MICHAEL BRAUN to Middle Aged
This is a "connection" page, showing publications MICHAEL BRAUN has written about Middle Aged.
Connection Strength
0.429
-
Long-term outcome of renal transplantation patients with Henoch-Schonlein purpura. Clin J Am Soc Nephrol. 2011 Aug; 6(8):2034-40.
Score: 0.021
-
Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis. 2011 Feb; 57(2):291-9.
Score: 0.020
-
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol. Clin Exp Med. 2026 Jan 21; 26(1):118.
Score: 0.014
-
Exploring perceptual disparities: A study on the level of understanding of colorectal cancer care among patients and healthcare professionals. Int J Colorectal Dis. 2026 Jan 08; 41(1):22.
Score: 0.014
-
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial. Clin Cancer Res. 2026 Jan 06; 32(1):214-223.
Score: 0.014
-
A clinical rule-based indicator to identify recurrence of colorectal cancer after curative resection using linked routinely collected national data. Cancer Epidemiol. 2026 Feb; 100:102962.
Score: 0.014
-
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. Clin Colorectal Cancer. 2026 03; 25(1):115-124.
Score: 0.014
-
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol. 2025 May; 26(5):629-640.
Score: 0.014
-
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. Mol Cancer. 2025 Mar 26; 24(1):96.
Score: 0.013
-
Value of hospital administrative data linked to national cancer registry records to identify metastatic disease at time of primary diagnosis in colorectal cancer patients: a study using national data in England. BMC Cancer. 2025 Mar 06; 25(1):407.
Score: 0.013
-
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025 Feb 14; 27(1):22.
Score: 0.013
-
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2025 02 03; 8(2):e2461639.
Score: 0.013
-
Oncological Outcomes From Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases. Clin Colorectal Cancer. 2025 06; 24(2):166-179.
Score: 0.013
-
Longitudinal Follow-Up of the Psychological Well-Being of Patients with Colorectal Cancer: Final Analysis of PICO-SM. Curr Oncol. 2024 12 11; 31(12):7903-7913.
Score: 0.013
-
Is early-onset colorectal cancer an evolving pandemic? Real-world data from a tertiary cancer center. Oncologist. 2024 12 06; 29(12):e1680-e1691.
Score: 0.013
-
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol. 2022 08 10; 40(23):2557-2567.
Score: 0.011
-
Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal Cancer. Clin Colorectal Cancer. 2022 06; 21(2):e117-e125.
Score: 0.011
-
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med. 2021 12; 10(23):8581-8594.
Score: 0.011
-
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. J Clin Oncol. 2021 11 20; 39(33):3705-3715.
Score: 0.011
-
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J Immunother Cancer. 2021 05; 9(5).
Score: 0.010
-
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast Cancer Res. 2021 03 18; 23(1):36.
Score: 0.010
-
The Impact of Changes in Service Delivery in Patients With Colorectal Cancer During the Initial Phase of the COVID-19 Pandemic. Clin Colorectal Cancer. 2021 06; 20(2):e120-e128.
Score: 0.010
-
Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of "Stemness" Programs and Local Inflammation. Clin Cancer Res. 2021 02 15; 27(4):1119-1130.
Score: 0.010
-
Functional Outcome Following Stroke Thrombectomy in Clinical Practice. Stroke. 2019 09; 50(9):2500-2506.
Score: 0.009
-
Role of Emergency Laparoscopic Colectomy for Colorectal Cancer: A Population-based Study in England. Ann Surg. 2019 07; 270(1):172-179.
Score: 0.009
-
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int J Cancer. 2020 01 01; 146(1):262-271.
Score: 0.009
-
Health-related quality of life in glomerular disease. Kidney Int. 2019 05; 95(5):1209-1224.
Score: 0.009
-
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. Am J Kidney Dis. 2019 02; 73(2):218-229.
Score: 0.009
-
Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment. Int J Stroke. 2019 06; 14(4):372-380.
Score: 0.009
-
Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. Radiother Oncol. 2019 02; 131:202-207.
Score: 0.009
-
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. J Natl Cancer Inst. 2018 06 01; 110(6):628-637.
Score: 0.008
-
Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and mortality in colorectal cancer surgery in England: population based cohort study. BMJ. 2018 May 02; 361:k1581.
Score: 0.008
-
Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.008
-
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin Oncol. 2017 Sep 10; 35(26):3046-3054.
Score: 0.008
-
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016 07; 53(7):465-71.
Score: 0.007
-
Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017 01; 26(1):74-80.
Score: 0.007
-
Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer. Breast Cancer Res Treat. 2015 Oct; 153(3):531-7.
Score: 0.007
-
Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.007
-
Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. 2008 May; 21(5):533-8.
Score: 0.004